OMEROS CORP Amortization of Debt Issuance Costs and Discounts
OMEROS CORP (OMER) reported Amortization of Debt Issuance Costs and Discounts of $1.39 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2024-05-15
- OMEROS CORP amortization of debt issuance costs and discounts for the quarter ending 2024-03-31 was $1.39M, a 190.78% increase year-over-year.
- OMEROS CORP amortization of debt issuance costs and discounts for the quarter ending 2023-12-31 was $403.00K, a 14.07% decline year-over-year.
- OMEROS CORP amortization of debt issuance costs and discounts for the quarter ending 2023-09-30 was $491.00K, a 6.51% increase year-over-year.
- OMEROS CORP amortization of debt issuance costs and discounts for the quarter ending 2023-06-30 was $482.00K, a 6.17% increase year-over-year.
- OMEROS CORP amortization of debt issuance costs and discounts for fiscal 2023 was $1.85M, a 1.26% increase from fiscal 2022.
- OMEROS CORP amortization of debt issuance costs and discounts for fiscal 2022 was $1.83M, a 7.90% increase from fiscal 2021.
- OMEROS CORP amortization of debt issuance costs and discounts for fiscal 2021 was $1.70M, a 85.44% decline from fiscal 2020.
- OMEROS CORP amortization of debt issuance costs and discounts for fiscal 2020 was $11.65M, a 26.18% increase from fiscal 2019.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2024-03-31 | $1.39M 10-Q · filed 2024-05-15 | $1.79M derived: sum of 2 quarters · filed 2024-05-15 | $2.28M derived: sum of 3 quarters · filed 2024-05-15 | $2.76M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | $403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $894.00K derived: sum of 2 quarters · filed 2024-04-01 | $1.38M derived: sum of 3 quarters · filed 2024-04-01 | $1.85M 10-K · filed 2024-04-01 |
| 2023-09-30 | $491.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $973.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.45M 10-Q · filed 2023-11-09 | $1.92M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | $482.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $959.00K 10-Q · filed 2023-08-09 | $1.43M derived: sum of 3 quarters · filed 2024-05-15 | $1.89M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | $477.00K 10-Q · filed 2024-05-15 | $946.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.41M derived: sum of 3 quarters · filed 2024-05-15 | $1.86M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $930.00K derived: sum of 2 quarters · filed 2024-04-01 | $1.38M derived: sum of 3 quarters · filed 2024-04-01 | $1.83M 10-K · filed 2024-04-01 |
| 2022-09-30 | $461.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $915.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.36M 10-Q · filed 2023-11-09 | $1.80M derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-06-30 | $454.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $900.00K 10-Q · filed 2023-08-09 | $1.34M derived: sum of 3 quarters · filed 2024-04-01 | $1.77M derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-03-31 | $446.00K 10-Q · filed 2023-05-09 | $886.00K derived: sum of 2 quarters · filed 2024-04-01 | $1.32M derived: sum of 3 quarters · filed 2024-04-01 | $1.75M derived: sum of 4 quarters · filed 2024-04-01 |
| 2021-12-31 | $440.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $874.00K derived: sum of 2 quarters · filed 2024-04-01 | $1.30M derived: sum of 3 quarters · filed 2024-04-01 | $1.70M 10-K · filed 2024-04-01 |
| 2021-09-30 | $434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $860.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.26M 10-Q · filed 2022-11-09 | $4.74M derived: sum of 4 quarters · filed 2023-03-13 |
| 2021-06-30 | $426.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $822.00K 10-Q · filed 2022-08-09 | $4.30M derived: sum of 3 quarters · filed 2023-03-13 | $7.31M derived: sum of 4 quarters · filed 2023-03-13 |
| 2021-03-31 | $396.00K 10-Q · filed 2022-05-10 | $3.88M derived: sum of 2 quarters · filed 2023-03-13 | $6.89M derived: sum of 3 quarters · filed 2023-03-13 | $9.51M derived: sum of 4 quarters · filed 2023-03-13 |
| 2020-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $6.49M derived: sum of 2 quarters · filed 2023-03-13 | $9.12M derived: sum of 3 quarters · filed 2023-03-13 | $11.65M 10-K · filed 2023-03-13 |
| 2020-09-30 | $3.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $5.64M derived: sum of 2 quarters · filed 2021-11-09 | $8.17M 10-Q · filed 2021-11-09 | $10.61M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $2.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $5.16M 10-Q · filed 2021-08-09 | $7.60M derived: sum of 3 quarters · filed 2022-03-01 | $9.96M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.53M 10-Q · filed 2021-05-10 | $4.97M derived: sum of 2 quarters · filed 2022-03-01 | $7.33M derived: sum of 3 quarters · filed 2022-03-01 | $9.56M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.80M derived: sum of 2 quarters · filed 2022-03-01 | $7.03M derived: sum of 3 quarters · filed 2022-03-01 | $9.23M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $4.59M derived: sum of 2 quarters · filed 2020-11-09 | $6.79M 10-Q · filed 2020-11-09 | $8.12M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $4.43M 10-Q · filed 2020-08-10 | $5.76M derived: sum of 3 quarters · filed 2021-03-01 | $7.57M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $2.20M 10-Q · filed 2020-05-11 | $3.53M derived: sum of 2 quarters · filed 2021-03-01 | $5.33M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.13M derived: sum of 2 quarters · filed 2021-03-01 | $5.63M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $4.31M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $2.50M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $4.19M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |